Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Making the decision to start therapy. On the level.

Steven McGuire

    BETA : Bulletin of Experimental Treatments for AIDS : a Publication of the San Francisco AIDS Foundation
    |September 25, 2004
    PubMed
    Summary

    Determining the optimal time for starting antiretroviral therapy (ART) for HIV is complex. Balancing treatment benefits against adverse effects, costs, and adherence challenges is crucial for effective HIV management.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Aging and HIV: a conversation with Dr. Glenn Treisman. Interview by Jennifer Heflin.

    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation·2012
    Same journal

    HIV/HCV coinfection: a new era of treatment.

    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation·2012
    Same journal

    Making sense of side effects.

    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation·2012
    Same journal

    Rilpivirine and complera: new first-line treatment options.

    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation·2012
    Same journal

    Becoming a positive parent: reproductive options for people with HIV.

    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation·2012
    Same journal

    Giving advocates a voice: an update on the U.S. Positive Women's Network. Interview by Jennifer Heflin.

    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation·2012

    Area of Science:

    • * Virology and Immunology
    • * Clinical Medicine
    • * Pharmacology

    Background:

    • * The optimal timing for initiating antiretroviral therapy (ART) in individuals with human immunodeficiency virus (HIV) remains a complex clinical decision.
    • * Antiretroviral medications, while life-prolonging, are associated with potential adverse effects, complicating the risk-benefit analysis.

    Discussion:

    • * Factors influencing the decision to start HIV treatment include drug toxicity, cost, patient adherence, and individual risk profiles.
    • * The evolving landscape of HIV management necessitates a nuanced approach to treatment initiation.
    • * This article critically examines the evidence and considerations surrounding the commencement versus deferral of anti-HIV therapy.

    Key Insights:

    • * The decision to initiate HIV treatment involves weighing potential benefits against significant risks and challenges.
    • * Adverse drug reactions, high medication costs, and adherence difficulties complicate the determination of an ideal treatment start time.
    • * A personalized approach is essential for optimizing HIV care and treatment outcomes.

    Outlook:

    • * Further research is needed to refine guidelines for ART initiation, particularly concerning long-term outcomes and patient-reported factors.
    • * Continued development of safer and more tolerable HIV medications may simplify treatment decisions.
    • * Exploring innovative strategies to improve adherence and reduce treatment costs will be vital for future HIV management.

    Related Experiment Videos